Sage’s Pipeline Prospects Narrow Further As Dalzanemdor Fails In Huntington’s
Third And Final Indication For NMDA Modulator
Sage will end development for dalzanemdor after it failed in a Phase II Huntington’s disease trial, leaving the company with one commercial drug and three early-stage assets.
